Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/5/2026
- S&P 500, Dow at record highs as Mideast hopes offset SpaceX, AMD drag
- SpaceX tumbles amid AI spending concerns; Musk outlines $1 trillion revenue target
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
- New report warns China transceiver ban would hurt U.S. AI giants
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Opendoor posts Q2 revenue rise as net loss widens year over year
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- Dave & Buster's names CFO Darin Harper as new CEO
- Dow, S&P 500 close at record on AI-linked earnings, Mideast deal hopes
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
Goldman on Pfizer (PFE) Post Metsera (MTSR) Deal: 'previously emphasized the importance of growing its footprint in internal medicines and primary care'
September 22, 2025 10:27 AM EDTGoldman Sachs analyst Asad Haider reiterated a Neutral rating and $27.00 price target on Pfizer (NYSE: PFE).
The analyst comments "This morning PFE announced plans to acquire Metsera (MTSR), a development stage obesity-focused biotech company with a portfolio of candidates (injectable and oral... More
Wolfe Research Comments on Path Forward for Pfizer (PFE) and Metsera (MTSR)
September 22, 2025 9:45 AM EDTWolfe Research analyst Alexandria Hammond reiterated an Underperform rating and $25.00 price target on Pfizer (NYSE: PFE).
The analyst comments "The path forward for Pfizer and Metsera. Topline data from VESPER-1 and interim data from VESPER-3 for MET-097i remain expected by the end of the month. It is our understanding,... More
